Literature DB >> 30932915

Empowering ASCI's support of physician-scientists through stronger institutional connections.

Kieren A Marr, W Kimryn Rathmell, John B Hawley, Karen D Guth.   

Abstract

The American Society for Clinical Investigation (ASCI), a nonprofit honorary society, was established to support physician-scientists by serving as a benchmark of excellence in medical research, a forum to celebrate advances in medicine, and a vehicle to communicate advances that bridge basic and translational research and their implementation across the growing myriad of medical specialties. A core intention of the Society is to engage the medical research community broadly through transparent communications of our activities and initiatives with the institutions that comprise the base for our membership. Recognizing the importance in identifying and actuating a strategy to support the Society's broad mission, the current leadership has undertaken a strategic plan that initiates with the goal of revamping its Institutional Representatives program. While the Society has grown with the historical privilege of close connections to institutions through an informal web created largely by the elected membership, we aim to improve institutional engagement towards overall goals of embracing and enhancing diversity of our community and implementing future collaborative programs to support physician-scientists. We briefly review ASCI's history, mission, and structure, and present the blueprint of the new Institutional Representatives program.

Year:  2019        PMID: 30932915      PMCID: PMC6436849          DOI: 10.1172/JCI128898

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  2 in total

1.  The ownership paradox: nurturing continuity and change for the future ASCI.

Authors:  Kieren A Marr
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

2.  A deliberate path toward diversity, equity, and inclusion within the ASCI.

Authors:  Lorraine B Ware; Kathleen L Collins; John B Hawley; Rexford S Ahima
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.